Safety is also a top priority for the use of nanomedicines in vivo. Fig. showed that the mice body weight in all groups was essentially unchanged and showed some increase during the treatment period, indicating the high biocompatibility and almost no toxicity of this system. In addition, the main organs in PBS group and EH@Ag2S +US group, including the lung, liver, spleen, kidney and heart, were subjected to H&E staining after treatment. No significant necrosis or obvious organ damage was detected, further demonstrating the high biocompatibility of this system (Fig. ). Moreover, to evaluate the long-term toxicity during the treatment period, blood routine and blood biochemical analysis were performed on mice treated with PBS group and EH@Ag2S +US group. Compared with the PBS group, the concentration of primary hepatic and renal function markers in EH@Ag2S +US group, were within the normal reference ranges (Fig. , Fig. ). These in vivo animal experiment results indicated that coassembled EH@Ag2S system with good biocompatibility had good antitumor effect and could activate immunity after treatment.